Care to elaborate why you switch from Openheimer to profit margins now...
we know that its one of the best hospital drugs and they sold aprox 2.8 billion in US and Novartis/Sandoz/MNTA have about 1 billion annualized sales so far of which MNTA gets to keep about 45% after all expenses are deducted. Compare that number to 45 million shares and think about it for a minute. Even if MNTA gets a net of 200-250 million after all the expenses its about 3 to 4 to possibly 5 per share in earnings. Lets say 4 in earnings for Lovenox and once Copaxone starts double it to another 4-5 in earnings.
You want people to believe that now that MNTA benefits - the margins are much smaller than when Sanofi sold it?
Market Data 
Markets 
AI
